PDSB — PDS Biotechnology Corporation

Is PDSB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

PDS Biotechnology Corporation (PDSB) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.21. The rating moved from Strong Oversold to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

PDS Biotechnology Corporation is a small-cap clinical-stage biotech with valuation highly dependent on a limited set of development milestones and external financing. While the broader sector shows pockets of strength that could create partnership or CDMO interest, the company faces typical early-stage biotech headwinds: short cash runway, high dilution risk, low liquidity, and binary clinical outcomes. Near-term price action will likely be driven by clinical updates, financing events, or partnership news; absent positive catalysts, downside from funding needs and negative trial/operational developments is the primary scenario. Market sentiment is currently modestly constructive for growth names, which may temporarily support speculative interest, but fundamental uncertainties remain the dominant risk.

Key factors

  • Early-stage clinical profile with value dependent on a small number of development milestones/readouts
  • Weak market capitalization and low stock price implying limited investor conviction and high volatility
  • Likely constrained cash runway and recurring need for dilutive financing for continued operations
  • Sector tailwinds for biologics and CDMO demand could indirectly benefit partnering or licensing opportunities
  • Potential near-term catalysts from clinical updates, partnerships, or licensing discussions that could create episodic upside
  • Macro environment has been mildly risk-on, which can temporarily lift speculative biotech names but does not change underlying fundamentals
  • Limited public information and minimal social/research coverage increases information asymmetry and event-driven risk

Risks

  • Clinical trial failures or disappointing data that materially reduce valuation
  • Severe cash burn leading to urgent equity raises and significant dilution for shareholders
  • Regulatory setbacks or slow review processes that delay timelines
  • Intense competition from better-funded oncology/biotech companies and platform technologies
  • Low liquidity and wide bid-ask spreads causing large price moves on small flows
  • Adverse shifts in investor sentiment or broader risk-off moves that disproportionately hit microcap biotech stocks
  • Partnerships or licensing negotiations failing to materialize or offering unfavorable terms
  • Limited transparency in public disclosures could increase perceived risk and reduce institutional interest

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PDSB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.